File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke

TitleReduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke
Authors
KeywordsC-reactive protein
Endothelial dysfunction
Isoflavone
Issue Date2008
PublisherOxford University Press. The Journal's web site is located at http://eurheartj.oxfordjournals.org/
Citation
European Heart Journal, 2008, v. 29 n. 22, p. 2800-2807 How to Cite?
AbstractAims: To investigate the effect of oral isoflavone supplement on vascular endothelial function in patients with established cardiovascular disease. Methods and results: A randomized, double-blinded, placebo-controlled trial was performed to determine the effects of isoflavone supplement (80 mg/day, n = 50) vs. placebo (n = 52) for 12 weeks on brachial flow-mediated dilatation (FMD) in patients with prior ischaemic stroke. Compared with controls, FMD at 12 weeks was significantly greater in isoflavone-treated patients [treatment effect 1.0%, 95% confidence interval (95% CI) 0.1-2.0, P = 0.035]. Adjusted for baseline differences in FMD, isoflavone treatment was independently associated with significantly less impairment of FMD at 12 weeks (odds ratio 0.32, 95% CI 0.13-0.80, P = 0.014). The absolute treatment effect of isoflavone on brachial FMD was inversely related to baseline FMD (r = -0.51, P < 0.001), suggesting that vasoprotective effect of isoflavone was more pronounced in patients with more severe endothelial dysfunction. Moreover, isoflavone treatment for 12 weeks resulted in a significant decrease in serum high-sensitivity (hs)-C-reactive protein level (treatment effect -1.7 mg/L, 95% CI -3.3 to -0.1, P = 0.033). Nevertheless, isoflavone did not have any significant treatment effects on nitroglycerin-mediated dilatation, blood pressure, heart rate, serum levels of fasting glucose and insulin, haemoglobin A1c, and oxidative stress as determined by serum superoxide dismutase, 8-isoprostane, and malondialdehyde (all P > 0.05). Conclusion: This study demonstrated that 12 week isoflavone treatment reduced serum hs-C-reactive protein and improved brachial FMD in patients with clinically manifest atherosclerosis, thus reversing their endothelial dysfunction status. These findings may have important implication for the use of isoflavone for secondary prevention in patients with cardiovascular disease, on top of conventional interventions. © The Author 2008.
Persistent Identifierhttp://hdl.handle.net/10722/92588
ISSN
2015 Impact Factor: 15.064
2015 SCImago Journal Rankings: 6.997
ISI Accession Number ID
Funding AgencyGrant Number
University of Hong Kong200507176137
Sun Chieh Yeh Heart Foundation
Outstanding Young Investigator Award of the University of Hong Kong
Great Liaison Limited, Hong Kong
Funding Information:

CRCG Small Project Funding of the University of Hong Kong ( Project No. 200507176137), Sun Chieh Yeh Heart Foundation, Outstanding Young Investigator Award of the University of Hong Kong, and an unconditional research donation from Great Liaison Limited, Hong Kong.

References

 

DC FieldValueLanguage
dc.contributor.authorChan, YHen_HK
dc.contributor.authorLau, KKen_HK
dc.contributor.authorYiu, KHen_HK
dc.contributor.authorLi, SWen_HK
dc.contributor.authorChan, HTen_HK
dc.contributor.authorFong, DYTen_HK
dc.contributor.authorTam, Sen_HK
dc.contributor.authorLau, CPen_HK
dc.contributor.authorTse, HFen_HK
dc.date.accessioned2010-09-17T10:50:57Z-
dc.date.available2010-09-17T10:50:57Z-
dc.date.issued2008en_HK
dc.identifier.citationEuropean Heart Journal, 2008, v. 29 n. 22, p. 2800-2807en_HK
dc.identifier.issn0195-668Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/92588-
dc.description.abstractAims: To investigate the effect of oral isoflavone supplement on vascular endothelial function in patients with established cardiovascular disease. Methods and results: A randomized, double-blinded, placebo-controlled trial was performed to determine the effects of isoflavone supplement (80 mg/day, n = 50) vs. placebo (n = 52) for 12 weeks on brachial flow-mediated dilatation (FMD) in patients with prior ischaemic stroke. Compared with controls, FMD at 12 weeks was significantly greater in isoflavone-treated patients [treatment effect 1.0%, 95% confidence interval (95% CI) 0.1-2.0, P = 0.035]. Adjusted for baseline differences in FMD, isoflavone treatment was independently associated with significantly less impairment of FMD at 12 weeks (odds ratio 0.32, 95% CI 0.13-0.80, P = 0.014). The absolute treatment effect of isoflavone on brachial FMD was inversely related to baseline FMD (r = -0.51, P < 0.001), suggesting that vasoprotective effect of isoflavone was more pronounced in patients with more severe endothelial dysfunction. Moreover, isoflavone treatment for 12 weeks resulted in a significant decrease in serum high-sensitivity (hs)-C-reactive protein level (treatment effect -1.7 mg/L, 95% CI -3.3 to -0.1, P = 0.033). Nevertheless, isoflavone did not have any significant treatment effects on nitroglycerin-mediated dilatation, blood pressure, heart rate, serum levels of fasting glucose and insulin, haemoglobin A1c, and oxidative stress as determined by serum superoxide dismutase, 8-isoprostane, and malondialdehyde (all P > 0.05). Conclusion: This study demonstrated that 12 week isoflavone treatment reduced serum hs-C-reactive protein and improved brachial FMD in patients with clinically manifest atherosclerosis, thus reversing their endothelial dysfunction status. These findings may have important implication for the use of isoflavone for secondary prevention in patients with cardiovascular disease, on top of conventional interventions. © The Author 2008.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://eurheartj.oxfordjournals.org/en_HK
dc.relation.ispartofEuropean Heart Journalen_HK
dc.subjectC-reactive proteinen_HK
dc.subjectEndothelial dysfunctionen_HK
dc.subjectIsoflavoneen_HK
dc.subject.meshBrachial Artery - drug effects - physiology-
dc.subject.meshC-Reactive Protein - metabolism-
dc.subject.meshEndothelium, Vascular - drug effects-
dc.subject.meshIsoflavones - administration and dosage - therapeutic use-
dc.subject.meshSoybean Proteins - therapeutic use-
dc.titleReduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic strokeen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0195-668X&volume=29&issue=22&spage=2800&epage=2807&date=2008&atitle=Reduction+of+C-reactive+protein+with+isoflavone+supplement+reverses+endothelial+dysfunction+in+patients+with+ischaemic+stroke-
dc.identifier.emailChan, YH: chanwill@hku.hken_HK
dc.identifier.emailLau, KK: gkklau@hku.hken_HK
dc.identifier.emailYiu, KH: khkyiu@hku.hken_HK
dc.identifier.emailFong, DYT: dytfong@hku.hken_HK
dc.identifier.emailTse, HF: hftse@hkucc.hku.hken_HK
dc.identifier.authorityChan, YH=rp01313en_HK
dc.identifier.authorityLau, KK=rp01499en_HK
dc.identifier.authorityYiu, KH=rp01490en_HK
dc.identifier.authorityFong, DYT=rp00253en_HK
dc.identifier.authorityTse, HF=rp00428en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/eurheartj/ehn409en_HK
dc.identifier.pmid18812325-
dc.identifier.scopuseid_2-s2.0-56449087038en_HK
dc.identifier.hkuros174560-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-56449087038&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume29en_HK
dc.identifier.issue22en_HK
dc.identifier.spage2800en_HK
dc.identifier.epage2807en_HK
dc.identifier.eissn1522-9645-
dc.identifier.isiWOS:000260974200018-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChan, YH=22633700600en_HK
dc.identifier.scopusauthoridLau, KK=22635159600en_HK
dc.identifier.scopusauthoridYiu, KH=35172267800en_HK
dc.identifier.scopusauthoridLi, SW=13807028100en_HK
dc.identifier.scopusauthoridChan, HT=22633582100en_HK
dc.identifier.scopusauthoridFong, DYT=35261710300en_HK
dc.identifier.scopusauthoridTam, S=7202037323en_HK
dc.identifier.scopusauthoridLau, CP=7401968501en_HK
dc.identifier.scopusauthoridTse, HF=7006070805en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats